Our Mission

“One step further through precise gene-targeting”

siRNAgen Therapeutics Corporation is a startup company (recently spinout from Bioneer) focusing on the discovery and development of RNAi therapeutics through next-gen RNAi, SAMiRNA™ (Self-Assembled-Micelle inhibitory RNA) platform. Our mission is developing RNAi therapeutics for the patients who are suffering from serious unmet-need diseases through our SAMiRNA™ technology. We are endeavoring to make disease-modifying-drugs, in order to treat disease itself fundamentally through our innovative SAMiRNA™ technology. SAMiRNA™ is a novel siRNA nanoparticle composed of hydrophilic and hydrophobic conjugates at each ends of siRNA, which makes spherical nanoparticle spontaneously. SAMiRNA has 3 major advantages over the other siRNA therapeutics in delivery (more deliverable to inflamed tissue and neoplasia), side effect (no innate immune stimulation), and much lower manufacturing cost.

Our pipeline of SAMiRNA-Areg (Amphiregulin) drug is focused on chronic fibrotic inflammatory diseases, such as IPF, RIPF, CKD and NASH, and anti-proliferative cancer therapy.


  • RNAi-Areg (Phase I,2020)
  • RNAi-NF
  • RNAi-Wnt
  • RNAi-Ixxx

  Target Indications

  • Anti-fibrotic (Scar/Psori/DNP/IPF/NASH/RIF/Ssc)
  • Anti-proliferative (Pan/C-R/G/Br/Ov Cancer with Areg↑)
  • Dengue fever
  • R.A
  • A.A
  • Sepsis
  • Ank Spond
  • D.M
  • CNS